Studies Reignite Debate over Avastin in Breast Cancer (CME/CE)

(MedPage Today) — Women with HER2-negative metastatic breast cancer had significantly higher rates of pathologic complete response when bevacizumab was added to neoadjuvant chemotherapy, two large clinical trials showed.